Brokerages Set INmune Bio, Inc. (NASDAQ:INMB) Price Target at $8.00

INmune Bio, Inc. (NASDAQ:INMB) has been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $8.00.

A number of research analysts recently issued reports on the stock. Lucid Cap Mkts upgraded shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. Wall Street Zen raised shares of INmune Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th.

Hedge Funds Weigh In On INmune Bio

A number of hedge funds have recently modified their holdings of the business. Virtu Financial LLC acquired a new stake in INmune Bio in the fourth quarter valued at $32,000. XTX Topco Ltd lifted its holdings in INmune Bio by 41.3% during the 4th quarter. XTX Topco Ltd now owns 68,865 shares of the company’s stock worth $107,000 after buying an additional 20,121 shares during the period. Quadrature Capital Ltd acquired a new position in INmune Bio during the 4th quarter worth about $26,000. Jain Global LLC bought a new stake in shares of INmune Bio in the 4th quarter valued at about $66,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of INmune Bio by 20.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock valued at $78,000 after buying an additional 8,427 shares during the last quarter. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Price Performance

Shares of INMB opened at $1.21 on Thursday. INmune Bio has a 12-month low of $1.09 and a 12-month high of $11.64. The business has a 50-day simple moving average of $1.37 and a two-hundred day simple moving average of $1.63. The stock has a market cap of $32.16 million, a PE ratio of -0.64 and a beta of 0.88.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.09. On average, equities research analysts expect that INmune Bio will post -2.24 EPS for the current year.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.